FDA grants fast track status for GC Biopharma and Novel Pharma’s GC1130A
This development follows the clearance for an investigational new drug (IND) application by the FDA for the asset last month. The fast track status is expected to expedite
Quadram Institute Bioscience and SKAN Research Trust have embarked on a collaborative project to develop new microbial therapies using advanced genetic sequencing platform.